Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Non Operating Income (2022 - 2025)

Verrica Pharmaceuticals has reported Other Non Operating Income over the past 4 years, most recently at -$889000.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at -$889000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$890000.0 (down 7990.91% YoY), and the annual figure for FY2025 was -$3000.0, up 82.35%.
  • Other Non Operating Income for Q4 2025 was -$889000.0 at Verrica Pharmaceuticals, down from -$1000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for VRCA hit a ceiling of $49000.0 in Q4 2023 and a floor of -$1.4 million in Q3 2022.
  • Median Other Non Operating Income over the past 4 years was -$9000.0 (2022), compared with a mean of -$293375.0.
  • Peak annual rise in Other Non Operating Income hit 800.0% in 2023, while the deepest fall reached 96.52% in 2023.
  • Verrica Pharmaceuticals' Other Non Operating Income stood at -$7000.0 in 2022, then skyrocketed by 800.0% to $49000.0 in 2023, then crashed by 122.45% to -$11000.0 in 2024, then tumbled by 7981.82% to -$889000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$889000.0 (Q4 2025), -$1000.0 (Q2 2025), and -$11000.0 (Q1 2024) per Business Quant data.